Balaxi Pharmaceuticals Ltd (BALAXI) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Balaxi Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 12 Nov 2026, 5:30 am
Balaxi Pharmaceuticals Schedules Board Meeting to Approve Half-Yearly Results Balaxi Pharmaceuticals Ltd. has informed the exchange that its Board of Directors will meet on 12th Nov'26. The board will consider and approve the company's half-yearly unaudited financial results for the period ended Sep'26, alongside other general business matters.
To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters.
Intimation · 12 Nov 2026, 5:30 am
Balaxi Pharmaceuticals Schedules Board Meeting for Q2 FY27 Financial Results Balaxi Pharmaceuticals Limited has scheduled a Board of Directors meeting on 12th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for Q2 and H1 ended 30th Sep'26 (FY26-27). In compliance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed for designated persons from 1st Oct'26 until 48 hours post the formal declaration of the financial results.
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended September 2026."
Others (Uncategorized) · 07 Oct 2026, 5:45 am
Balaxi Pharmaceuticals Reports Nil Physical Share Transfer Re-Lodgements for Sep'26 Balaxi Pharmaceuticals submitted its RTA report from Aarthi Consultants for the period ended Sep'26 regarding the re-lodgement of physical share transfer requests pursuant to SEBI circular dated 30th Jan'26. The company reported nil requests received, processed, approved, or rejected during the month under the special window.
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended August 2026 .'.
Others (Uncategorized) · 07 Sept 2026, 10:41 pm
Balaxi Pharmaceuticals Reports Nil Physical Share Transfer Re-Lodgements for Aug'26 Balaxi Pharmaceuticals submitted its RTA report via Aarthi Consultants Pvt Ltd for the period ended Aug'26, complying with SEBI Circular dated 30th Jan'26 regarding the re-lodgement of transfer requests for physical shares. During the month, the company recorded nil requests received, nil processed, nil approved, and nil rejected under the special SEBI window, resulting in no pending physical share transfer activity.
Balaxi Pharmaceuticals Limited has informed the Exchange about the receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation Manufacturing Facility.
Others (Uncategorized) · 31 Aug 2026, 6:28 pm
Balaxi Pharma Receives WHO-GMP Certification For First Formulation Facility Balaxi Pharmaceuticals has received WHO-GMP certification for its first formulation manufacturing facility in Jadcherla, Hyderabad. The certification, issued by Telangana's Licensing Authority on 27th Aug'26, is valid until 26th Aug'29. This marks a key milestone, enabling the company to establish its own manufacturing capabilities. Balaxi has commenced manufacturing of initial products and will expand its portfolio for international markets. This development strengthens its quality credentials and is expected to positively impact operations without any adverse effects on existing business.
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Change in Director(s) of the company.
Change in Management · 25 Aug 2026, 5:06 am
Balaxi Pharmaceuticals Re-appoints Independent Director Balaxi Pharmaceuticals (NSE: BALAXI) announced that members at its 83rd AGM on 24th Aug'26 approved the re-appointment of Ms. Akshita Ostwal as an Independent Director. Her second five-year term is effective from 05th Sep'26 through 04th Sep'31. Ms. Ostwal, with over ten years of corporate and IPR law experience, is the founder of Akshita Surana & Associates, a company secretarial firm. The company confirmed she is not debarred by SEBI or any other authority from holding a directorship.
BALAXI PHARMACEUTICALS LIMITED has submitted the Exchange a copy Srutinizers Report of Annual General Meeting held on 24th August, 2026. Further, the company has informed the Exchange regarding Voting Results.
Annual General Meeting · 25 Aug 2026, 4:45 am
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Proceedings of the 83rd Annual General Meeting held on 24th August, 2026
Annual General Meeting · 25 Aug 2026, 4:25 am
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Corrigendum to Notice of the 83rd Annual General Meeting.
Annual General Meeting · 10 Aug 2026, 5:50 pm
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended July 2026".
Others (Uncategorized) · 08 Aug 2026, 3:35 am
Balaxi Pharma: No Physical Share Transfer Requests in July 2026 Balaxi Pharmaceuticals submitted its Registrar and Transfer Agent (RTA) report on 07 Aug'26 for the period ending Jul'26. The report, mandated by a SEBI circular, confirms that no requests were received, processed, approved, or rejected for the re-lodgement of physical share transfers during the month. This filing indicates nil activity under the special window for physical share transfers.
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation
Investor Presentation · 06 Aug 2026, 9:47 pm
Balaxi Pharmaceuticals Reports Strong Q1 FY27 Revenue Growth and Margin Expansion Balaxi Pharma's Q1 FY27 consolidated revenue grew 14.1% YoY to ₹80.68 crore, while PAT surged 347% to ₹1.29 crore. Gross margin expanded by 241 bps to 46.5%, driven by improved business mix and market diversification. The company commenced commercial production at its new Hyderabad formulation facility, which has approvals for 31 products. Management highlighted its focus on institutional business, portfolio expansion, and backward integration, alongside a strategic exit from the ancillary building hardware business to improve operational performance.
Balaxi Pharmaceuticals Limited has informed the Exchange regarding Progress of the Company's First Pharmaceutical Formulation Plant at Jadcherla, Hyderabad .
Outcome · 05 Aug 2026, 7:31 pm
Balaxi Pharmaceuticals Starts Commercial Production at Jadcherla Plant Balaxi Pharmaceuticals commenced commercial production at its Jadcherla formulation plant on 05 Aug'26, initially with two products. The company has received manufacturing permissions for 29 additional products, expanding its approved portfolio to 31. It is also on track for WHO-GMP certification following a regulatory audit in Jul'26. For Q1'FY27, consolidated revenue grew 14% YoY to Rs. 8,068 lakhs, while net profit rose 348% YoY to Rs. 129.74 lakhs. Standalone operations reported a net loss of Rs. 125.32 lakhs versus a profit previously.
Balaxi Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on 05th August, 2026.
Outcome · 05 Aug 2026, 7:25 pm
Balaxi Pharma Commences Production at New Plant; Q1FY27 Profit Jumps Balaxi Pharma reported Q1FY27 consolidated net profit of ₹129.74 lakhs, up 347% YoY from ₹29.01 lakhs. Revenue from operations grew 14% YoY to ₹8,068.18 lakhs. The company commenced commercial production at its new Jadcherla plant with two products. It has received manufacturing permissions for 29 additional products, expanding its portfolio to 31. The facility underwent a WHO-GMP audit in Jul'26, and the company is on track for certification, which will support future growth and strengthen manufacturing credentials.
Balaxi Pharmaceuticals Limited has submitted to the Exchange, the financial results for the quarter ended 30th June, 2026.
Outcome · 05 Aug 2026, 7:21 pm
Balaxi Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 8,068 (+14.1% YoY | +14.1% QoQ) ■ EBITDA: 466 (+12.4% YoY | +3731.1% QoQ) ■ EBITDA Margin (%): 5.8 (-9 bps YoY | +561 bps QoQ) ■ PAT: 130 (+347.2% YoY | +111.7% QoQ) ■ EPS (INR): 0.24 (+380.0% YoY | +118.2% QoQ)
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding 'Balaxi Pharmaceuticals Limited has informed the Exchange regarding 'BRSR for FY 2025-26'.'.
Others (Uncategorized) · 31 Jul 2026, 6:50 pm
Balaxi Pharmaceuticals FY26 Sustainability Report Highlights Operational & ESG Metrics Balaxi Pharmaceuticals filed its Business Responsibility & Sustainability Report for FY26 on Jul 31, '26. The report covers the standalone entity, whose primary activity is international wholesale trading of pharmaceutical products (100% of turnover). Key FY26 metrics include total energy consumption of 1391.82 Giga Joules and 62 permanent employees. A new manufacturing facility established in FY26 is expected to commence operations in H1 FY27. Balaxi acquired Balaxi Healthcare Nicaragua on Apr 1, '25, and struck off a step-down subsidiary in Centrafrique.
Balaxi Pharmaceuticals Limited has informed the Exchange regarding Notice of 83rd Annual General Meeting to be held on 24th August, 2026.
Annual General Meeting · 31 Jul 2026, 6:30 pm
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Aug-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Other business.
Intimation · 05 Aug 2026, 5:30 am
Balaxi Pharmaceuticals Board to Approve Q1FY27 Results on 05-Aug'26 Balaxi Pharmaceuticals Ltd. has scheduled a board meeting for 05-Aug'26 to consider and approve its unaudited financial results for the quarter ending Jun'26. Other business matters will also be discussed.
To consider and approve the unaudited standalone and consolidated financial results of the Company for the first quarter ended 30th June, 2026 of the Financial Year 2026-27, and other business matters.
Intimation · 29 Jun 2026, 5:30 am
Balaxi Pharma Board to Approve Q1FY27 Results on 05-Aug-26 Balaxi Pharmaceuticals (NSE: BALAXI) has scheduled a Board of Directors meeting for 05-Aug-26 to consider and approve its unaudited standalone and consolidated financial results for the first quarter ended 30-Jun-26. The insider trading window has been closed from 01-Jul-26 and will reopen 48 hours after the results are declared. This meeting is a key event for the company's Q1 performance evaluation for the financial year 2026-27.
The Exchange had sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Others (Uncategorized) · 14 Jul 2026, 5:15 pm
Balaxi Pharma Corrects FY26 Results Following Exchange Discrepancy Notice Balaxi Pharmaceuticals issued a clarification on 30th Jun'26, addressing discrepancies in its FY26 results filed on 28th May'26. The company corrected errors in Standalone and Consolidated filings for the period ending 31st Mar'26. Key corrections involved Standalone Employee Benefit Expense, which was revised to INR 229.66 Lakhs, and Consolidated Other Comprehensive Income figures, where erroneous negative signs were removed. These changes rectified the Total Comprehensive Income for Q4FY26 to a positive INR 905.74 Lakhs from a negative INR 783.17 Lakhs. Revised XBRL filings have been submitted.
'BALAXI PHARMACEUTICALS LIMITED' has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended June 2026 .'.
Others (Uncategorized) · 09 Jul 2026, 10:41 pm
Balaxi Pharmaceuticals Reports NIL Physical Share Transfer Requests for Jun'26 Balaxi Pharmaceuticals submitted its RTA report on the re-lodgement of physical share transfer requests for the period ended Jun'26, as per SEBI regulations. The report, provided by Aarthi Consultants Private Limited, confirms that there were NIL requests received, processed, approved, or rejected during the month. This filing fulfills the company's compliance requirements with the SEBI circular dated 30th Jan'26.